Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
CTR20200192Phase 3Active
- Sponsor
- Junshi Biosciences
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab, bevacizumab, sorafenib in hepatocellular carcinoma (HCC), sponsored by Junshi Biosciences. Started Mar 2021; status: active.
02
Drugs
toripalimabbevacizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20200192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200192.